Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs

Psychopharmacology

Volumn 131, Issue 2, 1997, Pages 180-186

  Griebel, Guy ^a   Perrault, Ghislaine ^a   Sanger, David J ^a  

^a SANOFI   (France)

Author keywords

Acute and chronic treatments; Anxiety; Befloxatone; Defensive behaviours; Flight; Moclobemide; Panic; Reversible monoamine oxidase inhibitors; Risk assessment; Swiss mouse

Indexed keywords

ANXIOLYTIC AGENT; BEFLOXATONE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY NEUROSIS; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DEFENSIVE BEHAVIOR; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL MODEL; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PANIC; PRIORITY JOURNAL;

ANIMALS; ANXIETY; AVOIDANCE LEARNING; BENZAMIDES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITORS; OXAZOLES; PANIC DISORDER; RATS;

EID: 0030946581     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050282     Document Type: Article

References (35)

1. Altemus M, Glowa JR, Murphy DL (1993) Attenuation of food-restriction-induced running by chronic fluoxetine treatment. Psychopharmacol Bull 29:397-400
2. Berger P, Amering M, Dantendorfer K, Alf C, Kutzer M, Katschnig H (1991) Moclobemide in panic disorder. Presented at the 5th World Congress of Biological Psychiatry, Florence, Italy, June 9-14
3. Blanchard DC, Blanchard RJ, Rodgers RJ (1991) Risk assessment and animal models of anxiety. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology. Birkhäuser Basel, pp 117-134
4. Blanchard RJ, Yudko EB, Rodgers RJ, Blanchard DC (1993) Defence system psychopharmacology: an ethological approach to the pharmacology of fear and anxiety. Behav Brain Res 58:155-165
5. Buller R (1995) Reversible inhibitors of monoamine oxidase A in anxiety disorders. Clin Neuropharmacol 18:838-S44
6. Caille D, Bergis OE, Fankhauser C, Gardes A, Adam R, Charieras T, Grosset A, Rovei V, Jarreau FX (1996) Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. J Pharmacol Exp Ther 277:265-277
7. Curet O, Damoiseau G, Aubin N, Sontag N, Rovei V, Jarreau FX (1996) Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. J Pharmacol Exp Ther 277:253-264
8. Den Boer JA, Westenberg HG (1988) Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3:59-74
9. Dilbaz N, Arihan AG (1993) Reversible MAO inhibitor in the treatment of panic disorder. Presented at The 9th World Congress of Psychiatry, Rio de Janeiro, Brazil, June 6-12
10. Finberg JPM (1995) Pharmacology of reversible and selective inhibitors of monoamine oxidase type A. Acta Psychiatr Scand Suppl 386:8-13
11. Fontana DJ, Commissaris RL (1988) Effects of acute and chronic imipramine administration on conflict behavior in the rat: a potential "animal model" for the study of panic disorder? Psychopharmacology 95:147-150
12. Fontana DJ, Carbary TJ, Commissaris RL (1989) Effects of acute and chronic anti-panic drug administration on conflict behavior in the rat. Psychopharmacology 98:157-162
13. Giesecke ME (1990) Overcoming hypersensitivity to fluoxetine in a patient with panic disorder (letter). Am J Psychiatry 147: 532-533
14. Graeff FG (1991) Neurotransmitters in the dorsal periaqueductal grey and animal models of panic anxiety. In: Briley M, File SE (eds) New concepts in anxiety. CRC Press, New York, pp 288-307
15. Griebel G, Blanchard DC, Agnes RS, Blanchard RJ (1995a) Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology 120: 57-66
16. Griebel G, Blanchard DC, Jung A, Blanchard RJ (1995b) A model of "antipredator" defence in Swiss-Webster mice: effects of benzodiazepine receptor ligands with different intrinsic activities. Behav Pharmacol 6:732-745
17. Griebel G, Blanchard DC, Jung A, Lee JC, Masuda CK, Blanchard RJ (1995c) Further evidence that the Mouse Defence Test Battery is useful for screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam. Neuropharmocology 34:1625-1633
18. 2A antagonist pirenperone. Pharmacol Biochem Behav 51:235-244
19. Griebel G, Blanchard DC, Blanchard RJ (1996a) Evidence that the behaviors in the Mouse Defence Test Battery relate to different emotional states. A factor analytic study. Physiol Behav 60: 1255-1260
20. Griebel G, Blanchard DC, Blanchard RJ (1996b) Predator-elicited flight responses in Swiss-Webster mice: an experimental model of panic attacks. Prog Neuropsychopharmacol Biol Psychiatr 20:185-205
21. Griebel G, Sanger DJ, Perrault G (1996c) The Mouse Defence Test Battery: evaluation of the effects of non-selective and BZ-1 (ω1) selective, benzodiazepine receptor ligands. Behav Pharmacol 7:560-572
22. Griebel G, Sanger DJ, Perrault G (1996d) Genetic differences in the Mouse Defence Test Battery. Aggress Behav (in press)
23. Hendrie CA, Neill JC (1991) An animal model of panic disorder. J Psychopharmacol 6:125
24. Jenck F, Moreau JL, Martin JR (1995) Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Res 57: 181-191
25. Liebowitz MR, Hollander E, Schneier F, Campeas R, Welkowitz L, Hatterer J, Fallon B (1990) Reversible and irreversible monoamine oxidase inhibitors in other psychiatrie disorders. Acta Psychiatr Scand Suppl 360:29-34
26. Martin P (1993) Effects of anxiolytic and antidepressant drugs in an animal model of panic. In: Hamon M, Ollat H, Thiébot MH (eds) Anxiety: neurobiology, clinical and therapeutic perspectives. Les éditions INSERM/John Libbey Eurotext, Paris, pp 203-204
27. Molewijk HE, Van der Poel AM, Mos J, Vanderheyden JAM, Olivier B (1995) Conditioned ultrasonic distress vocalizations in adult male rats as a behavioural paradigm for screening anti-panic drugs. Psychopharmacology 117:32-40
28. Olivier B (1992) Animal models in obsessive compulsive disorder. Int Clin Psychopharmacol 7 [Suppl 1]:27-29
29. Priest RG, Gimbrett R, Roberts M, Steinert J (1995) Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders. Acta Psychiatr Scand Suppl 386:40-43
30. Rapoport JL (1992) Animal models of obsessive compulsive disorder. Clin Neuropharmacol 15 [Suppl 1 Pt A]:261A-262A
31. Rapoport JL, Ryland DH, Kriete M (1992) Drug treatment of canine acral lick. An animal model of obsessive-compulsive disorder. Arch Gen Psychiatry 49:517-521
32. Servatius RJ, Ottenweller JE, Natelson BH (1995) Delayed startle sensitization distinguishes rats exposed to one or three stress sessions: further evidence toward an animal model of PTSD. Biol Psychiatry 38:539-546
33. Westenberg HGM, Den Boer JA (1993a) Serotonin in anxiety related disorders. In: Vanhoutte PM, Saxena PR, Paoletti R, Brunello N, Jackson AS (eds) Serotonin, from cell biology to pharmacology and therapeutics. Kluwer, Dordrecht, pp 249-254
34. Westenberg HGM, Den Boer JA (1993b) Serotonergic basis of panic disorder. In: Montgomery SA (ed) Psychopharmacology of panic. Oxford University Press, Oxford, pp 91-109
35. Yadin E, Friedman E, Bridger WH (1991) Spontaneous alternation behavior: an animal model for obsessive-compulsive disorder? Pharmacol Biochem Behav 40:311-315